License Performance Obligation was NewAmsterdam Pharma’s largest revenue line in fiscal 2022, bringing in $280.50M of $304.50M (92%).
| Separate Management Entities | FY 2022 |
|---|---|
| License Performance Obligation | $280.50M |
| Rd Performance Obligations | $12.00M |
| Research & Development Performance Obligation | $12.00M |
| Total | $304.50M |
NewAmsterdam Pharma brought in $304.50M from its three revenue lines in fiscal 2022, the year ended December 31, 2022. License Performance Obligation was the largest at $280.50M (92.1%), ahead of Rd Performance Obligations at $12.00M (3.9%) and Research & Development Performance Obligation at $12.00M (3.9%).
NewAmsterdam Pharma (NAMS) reports its revenue by separate management entities. In fiscal 2022, License Performance Obligation was its largest revenue line, bringing in $280.50M (92.1% of the total), followed by Rd Performance Obligations at $12.00M (3.9%).
License Performance Obligation was NewAmsterdam Pharma's largest revenue line in fiscal 2022, bringing in $280.50M, or 92.1% of the $304.50M total across its three revenue lines.
Every figure comes from NewAmsterdam Pharma's annual financial filings, as reported. Each line keeps the name NewAmsterdam Pharma gives it, and years follow its fiscal calendar.
NewAmsterdam Pharma's revenue by separate management entities goes back to fiscal 2022, with figures through fiscal 2022. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.